var data={"title":"Cloxacillin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cloxacillin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5933?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cloxacillin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cloxacillin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153884\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cloxi;</li>\n      <li>Cloxacillin for injection;</li>\n      <li>Novo-Cloxin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153901\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153887\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4 to 6 weeks. The intravenous route should be used for severe infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Susceptible infections (manufacturer&rsquo;s labeling):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 to 500 mg every 6 hours (maximum adult dose: 6 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 250 to 500 mg every 6 hours (maximum adult dose: 6 g/day). <b>Note:</b> Doses up to 2 g every 4 to 6 hours or 8 to 12 g/day in divided doses have been recommended by others (see indication-specific dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 250 to 500 mg every 6 hours (maximum adult dose 6 g/day). <b>Note:</b> Doses up to 2 g every 4 to 6 hours or 8 to 12 g/day in divided doses have been recommended by others (see indication-specific dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Dosing recommendations of World Health Organization (WHO) unless otherwise noted:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Arthritis (septic) (off-label dosing) (WHO 2001):</b> Empiric therapy: Adults: IM, IV: 2 g every 6 hours with concomitant ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA): </b> IM, IV: 2 g every 6 hours for 2 to 3 weeks; <b>Note:</b> Cloxacillin oral therapy of 1 g every 6 hours may be used to complete therapy if parenteral therapy is discontinued prior to 2 to 3 week duration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Endocarditis (MSSA) (off-label dosing):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Native valve:</i> 2 g every 4 hours for 6 weeks; may give with gentamicin for initial 5 days (Choudri 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Prosthetic valve:</i> 2 g every 4 hours for 6 weeks; give with gentamicin for 2 weeks and rifampin for 6 weeks (Choudri 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Uncomplicated endocarditis in IV drug users:</i> 2 g every 4 hours for 4 weeks and gentamicin for initial 5 days <b>or</b> 2 g every 4 hours and gentamicin both given for 2 weeks total (Choudri 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Osteomyelitis (MSSA) (off-label dosing) (WHO 2001):</b> IM, IV: 2 g every 6 hours for 4 to 6 weeks (preferred) <b>or</b> for a minimum of 14 days, <b>followed by</b> 1 g every 6 hours orally to complete 4 to 6 weeks of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Pneumonia (MSSA) (off-label dosing) (WHO 2001):</b> IM, IV: 1 to 2 g every 6 hours for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Pneumonia (nosocomial) (off-label dosing) (WHO 2001):</b>  Empiric therapy: IV: 1 to 2 g every 6 hours with concomitant gentamicin for 7 days (add vancomycin for 10 to 14 days if in a hospital with a high prevalence of MRSA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Septicemia (off-label dosing) (WHO 2001):</b> Empiric therapy: IV: 2 g every 4 to 6 hours with concomitant gentamicin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Skin and soft tissue infections (off-label dosing) (WHO 2001):</b> Empiric therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contaminated soft tissue injuries: IM, IV: 2 g every 6 hours for 5 to 10 days with concomitant gentamicin and metronidazole; with clinical improvement, may switch to oral cloxacillin 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Localized purulent skin lesions, impetigo: Oral: 250 to 500 mg every 6 hours for 5 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pyomyositis: IM, IV: 2 g every 6 hours for 5 to 10 days; with clinical improvement, may switch to oral cloxacillin 500 mg every 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153895\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4 to 6 weeks. The intravenous route should be used for severe infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Susceptible infections (manufacturer&rsquo;s labeling): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;20 kg: 25 to 50 mg/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &gt;20 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;20 kg: 25 to 50 mg/kg/day in divided doses every 6 hours. <b>Note:</b> Doses up to 50 mg/kg/dose every 4 to 6 hours or 200 mg/kg to 300 mg/kg/day in divided doses have been recommended by others (Nunn 2007; St. John 1981) (also see indication-specific dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &gt;20 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Dosing recommendations of World Health Organization (WHO) unless otherwise noted:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Arthritis (septic) (off-label dosing) (WHO 2001):</b> Empiric therapy: Infants &ge;2 months, Children, and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours with concomitant ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Infants &ge;2 months and Children &le;5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral cloxacillin 12.5 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 2 to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Children &gt;5 years and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours (maximum daily dose: 12 g/day) for 4 to 6 days or until clinical improvement, <b>followed by</b> oral cloxacillin 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 2 to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Endocarditis (MSSA) (off-label dosing) (WHO 2001):</b> Children and Adolescents: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 4 hours for 6 weeks; with concomitant gentamicin for initial 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Osteomyelitis (off-label dosing) (WHO 2001):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Haemophilus influenza</i> or unknown pathogen: Infants &ge;2 months and Children &le;5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral therapy with amoxicillin/clavulanate; total duration of therapy 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MSSA:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;2 months and Children &le;5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days until clinical improvement, <b>followed by</b> oral cloxacillin 12.5 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 3 to 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;5 years and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours (maximum daily dose: 12 g/day) for 4 to 6 days until clinical improvement, <b>followed by</b> oral cloxacillin 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours; total duration of therapy 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Salmonella spp:</i> Infants &ge;2 months and Children &le;5 years: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone for 4 to 6 days or until clinical improvement, <b>followed by</b> oral therapy with sulfamethoxazole/trimethoprim or amoxicillin or ciprofloxacin; total duration of therapy 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Pneumonia (MSSA) (off-label dosing) (WHO 2001):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Infants &ge;2 months and Children &le;5  years: Oral: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for at least 3 weeks with concomitant gentamicin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Children &gt;5 years and Adolescents: IM, IV: 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 10 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia (nosocomial) (off-label dosing) (WHO 2001):</b> Empiric therapy: Children and Adolescents: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours with concomitant gentamicin for 7 days (add vancomycin for 10 to 14 days if in a hospital with a high prevalence of MRSA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septicemia (off-label dosing) (WHO 2001):</b> Empiric therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;2 months to 5 years: IV: 50 mg/kg/dose (maximum: 2 g/dose) every 4 to 6 hours with concomitant ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;5 years and Adolescents: IV: 2 g every 4 to 6 hours with concomitant gentamicin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections (off-label dosing) (WHO 2001)</b>: Empiric therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contaminated soft tissue injuries: Children and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 5 to 10 days with concomitant gentamicin and metronidazole; with clinical improvement, may switch to oral cloxacillin 12.5 to 25 mg/kg/dose (maximum: 500 mg) every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Localized purulent skin lesions, impetigo:  Children and Adolescents: Oral: 12.5 to 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pyomyositis: Children and Adolescents: IM, IV: 25 to 50 mg/kg/dose (maximum: 2 g/dose) every 6 hours for 5 to 10 days; with clinical improvement, may switch to oral cloxacillin 12.5 to 25 mg/kg/dose (maximum: 500 mg/dose) every 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153888\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153889\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795886\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6051361\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Injection: 500 mg, 1000 mg, 2000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension Reconstituted, Oral: 125 mg/5 mL (60 mL, 100 mL, 200 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11218424\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6051127\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with water 1 hour before or 2 hours after meals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer slowly over 2 to 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Administer over 30 to 40 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153867\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial infections:</b> Treatment of bacterial infections including endocarditis, pneumonia, bone and joint infections, skin and soft-tissue infections, and sepsis that are caused by susceptible strains of  penicillinase-producing staphylococci.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Exhibits good activity against <i> Staphylococcus aureus</i>; has activity against many streptococci, but is less active than penicillin and is generally not used in clinical practice to treat streptococcal infections. Not effective against methicillin-resistant staphylococci.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153855\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Adverse effects may be reported as class effects rather than specific to cloxacillin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, lethargy, myoclonus, seizure (high doses and/or renal failure), twitching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, epigastric distress, flatulence, hairy tongue, loose stools, melanoglossia, nausea, oral candidiasis, pseudomembranous colitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, bone marrow depression, eosinophilia, granulocytopenia, hemolytic anemia, immune thrombocytopenia, leukopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction (immediate and delayed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Laryngospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis, renal insufficiency, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, laryngeal edema, sneezing, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153870\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cloxacillin, other penicillins, cephalosporins, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153852\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Although not reported with cloxacillin, the transport of penicillins across the blood-brain barrier may be enhanced by inflamed meninges or during cardiopulmonary bypass. An increased risk of myoclonia, seizures, or reduced consciousness may be observed in these patients (particularly those with renal failure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Penicillin use has been associated with hematologic disorders (eg, agranulocytosis, neutropenia, thrombocytopenia) believed to be a hypersensitivity phenomena. Reactions are most often reversible upon discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; rate of elimination is reduced. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high serum levels, particularly in the presence of renal impairment, may increase risk for seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: May have decreased renal clearance of cloxacillin; frequent evaluation of serum levels and of clinical status for adverse effects as well as frequent dosage adjustments may be necessary in this patient population. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299070\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153857\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9288&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6050842\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases cloxacillin absorption; serum levels are reduced by ~50%. Management: Administer with water on an empty stomach 1 hour before or 2 hours after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6050840\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Cloxacillin crosses the placenta and distributes into fetal tissue</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20613757\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cloxacillin is excreted into breast milk</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153863\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose; CBC with differential (prior to initiating therapy and weekly thereafter), periodic urinalysis,  BUN, creatinine, hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153851\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153869\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: ~50%; reduced by food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to most body fluids and bone; penetration into cells, into eye, and across normal meninges is poor; inflammation increases amount that crosses blood-brain barrier </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~94% (primarily albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to active and inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.5 to 1.5 hours; prolonged with renal impairment and in neonates </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153874\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Clox (BD);</li>\n      <li>Alclox (LK);</li>\n      <li>Ampiclox (NL);</li>\n      <li>An Mei LIn (CN);</li>\n      <li>Anaclosil (ES);</li>\n      <li>Apo-Cloxi (HK, SG);</li>\n      <li>Bioclox (IN);</li>\n      <li>Caxin (PH);</li>\n      <li>Clox (PH);</li>\n      <li>Cloxa (BD);</li>\n      <li>Cloxacap (HK, SG);</li>\n      <li>Cloxgen (TH);</li>\n      <li>Cloxidil (VN);</li>\n      <li>Cloxomed (TW);</li>\n      <li>Decalox (LK);</li>\n      <li>Ekvacillin (NO, SE);</li>\n      <li>Encloxil (PH);</li>\n      <li>Eraclox (PH);</li>\n      <li>Gaofen (CN);</li>\n      <li>Iclox (ZW);</li>\n      <li>Isoxacillin (MY);</li>\n      <li>Kaifa (CN);</li>\n      <li>Klox (IN);</li>\n      <li>Lidoxin (SG);</li>\n      <li>M-Clox (ET);</li>\n      <li>Meikam (ID);</li>\n      <li>monoclox (BH);</li>\n      <li>Monoclox (CY, JO, MY, TR, VN);</li>\n      <li>Orbenil (IL);</li>\n      <li>Orbenin (AE, BB, BD, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ES, ET, GH, GM, GN, GR, GY, IE, IQ, IR, JM, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Orbenine (FR);</li>\n      <li>Pannox (PH);</li>\n      <li>Penstapho N (BE);</li>\n      <li>Prostafilina A (PE);</li>\n      <li>Prostafilina-A (CO);</li>\n      <li>Prostaphlin-A (PH);</li>\n      <li>SPMC (LK);</li>\n      <li>Staflocil (FI);</li>\n      <li>Syntarpen (PL);</li>\n      <li>Ultraclox (BD);</li>\n      <li>Vamcloxil (PH);</li>\n      <li>Zeflodan (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apo-Cloxi (cloxacillin) [product monograph]. Weston, Ontario, Canada: Apotex Inc; November 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choudri SH, and The Endocarditis Care Plan Working Group, &ldquo;Consensus Guidelines for the Treatment of Infectious Endocarditis with Outpatient Parenteral Antibiotic Therapy,&rdquo; <i>Can J Infect Dis</i>, 2000, 11(Suppl D):4-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloxacillin for injection [product monograph]. Mississauga, Ontario, Canada: SteriMax Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enat R, Pollack S, Ben-Arieh Y, et al, &ldquo;Cholestatic Jaundice Caused by Cloxacillin: Macrophage Inhibition Factor Test in Preventing Rechallenge With Hepatotoxic Drugs,&rdquo; <i>Br Med J</i>, 1980, 280(6219):982-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/7417768/pubmed\" target=\"_blank\" id=\"7417768\">7417768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JD, Howard JB, and Shelton S, &ldquo;Oral Antibiotic Therapy for Skeletal Infections of Children. I. Antibiotic Concentrations in Suppurative Synovial Fluid,&rdquo; <i>J Pediatr</i>, 1978, 92(1):131-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/619055/pubmed\" target=\"_blank\" id=\"619055\">619055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nunn TR, Cheung WY, and Rollinson PD, &ldquo;A Prospective Study of Pyogenic Sepsis of the Hip in Childhood,&rdquo; <i>J Bone Joint Surg Br</i>, 2007, 89(1):100-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/17259425/pubmed\" target=\"_blank\" id=\"17259425\">17259425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pichichero ME, &ldquo;Group A Beta-Hemolytic Streptococcal Infections,&rdquo; <i>Pediatr Review</i>, 1998, 19(9):291-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/9745311/pubmed\" target=\"_blank\" id=\"9745311\">9745311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St. John MA and Prober CG, &ldquo;Side Effects Of Cloxacillin in Infants and Children,&rdquo; <i>Can Med Assoc J</i>, 1981, 125(5): 458-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/7284928/pubmed\" target=\"_blank\" id=\"7284928\">7284928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teva-Cloxacillin (cloxacillin) [product monograph]. Toronto, Canada: Teva Canada Limited; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westerman EL, Bradshaw MW, and Williams TW, &ldquo;Agranulocytosis During Therapy With Orally Administered Cloxacillin,&rdquo; <i>Am J Clin Pathol</i>, 1978, 69(5):559-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/655134/pubmed\" target=\"_blank\" id=\"655134\">655134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;World Health Organization Model Prescribing Information: Drugs Used in Bacterial Infections,&rdquo; 2001; http://www.who.int/medicinedocs/en/d/Js5406e. Accessed October 20, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cloxacillin-united-states-not-available-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9288 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F153884\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F153901\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F153887\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F153895\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F153888\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F153889\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795886\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F6051361\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11218424\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6051127\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F153867\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153855\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153870\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153852\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299070\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F153857\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F6050842\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6050840\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20613757\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F153863\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153851\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F153869\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F153874\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9288|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cloxacillin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Cloxacillin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}